Here, we found that Scu, the first small molecule agonist of IDH1, can directly target IDH1 to inhibit tumor cell growth and activate the tumor immune microenvironment by inhibiting tumor cell glycolysis. The gene discussed is IDH1; the disease is neoplasm.